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Abstract We present the case of 48-year-old woman
suffering from migraine with aura (MA) since menarche.
During her life the patient frequently presented catamenial
MA attacks with an increasing frequency during pregnancy
in particular in the second and third trimesters, and then
during breast-feeding. Treatment with oral contraceptive
(OC) for endometriosis and later with cyclophosphamide,
methotrexate, fluorouracil (CMF) for breast cancer pro-
duced a higher number of attacks. Instead, she referred an
improvement with gonadotropin releasing hormone agonist
(GnRH-a) for the treatment of endometriosis and then with
tamoxifen as hormonal therapy after mastectomy and
chemotherapy for breast cancer. We highlight the impor-
tance of physiological hormonal modification and
hormonal therapies on the course of MA.
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Introduction
The influence of ovarian hormone activity on migraine
with (MA) and without aura (MO) throughout the female
lifecycle is well known [1, 2]. Estrogenic production
induces dichotomy in the incidence of migraine between
the two genders at the time of puberty, which becomes
wider during the childbearing age and diminishes after
menopause [1]. In women, the attacks often begin at
menarche and then occur maximally in correlation with
menses as pure menstrual migraine or menstrual-related
migraine in a large amount of patients [3, 4]. Indeed, a
change in migraine pattern is frequently observed during
pregnancy [5, 6], puerperium [7] and after menopause [8,
9], and is related to hormonal therapies [10]. We present
the case of a woman with a 36-year history of migraine
with aura and describe the effect on the attacks of the
hormonal physiological modifications and of the various
hormonal therapeutic treatments that rarely could be found
in a single individual.
Case report
A 48-year old woman presented at our Headache Centre for
a long-standing history of migraine with aura (ICHD-II)
[11]. She experienced her first episode by the age of
12 years, a few months after menarche. The attacks were
characterized by gradual onset of flickering lights localized
over the temporal aspect of both visual fields with an
average duration of 30–40 min, followed within a half-
hour by bilateral, throbbing and moderate to severe head-
ache, accompanied by nausea, photophobia and
phonophobia with a duration of about 6 h. At the begin-
ning, the attacks usually occurred during the menstrual
period with a frequency of one episode every other month.
Other trigger factors were reported, including emotional
stresses and difficulties with study and, later on, with her
work as a clerk. The frequency of attacks remained quite
unchanged until the age of 26 when she became pregnant.
During the second and third trimester, the patient
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experienced an increased frequency with at least two epi-
sodes a month, or more, in the last month prior to delivery.
The attacks remained unchanged during puerperium and
the 4 months of breast-feeding, after which the episodes
persisted with a frequency of once a month. At the age of
31, the patient was diagnosed with ovarian endometriosis
for which she was started on oral contraceptives (OC).
During the 6-month period of OC therapy, the attacks
markedly worsened, presenting with an almost weekly
frequency. For this reason, a prophylactic therapy with
lisuride at the dosage of 0.025 mg tid was added, without
relevant improvement. Afterwards, the OC therapy was
stopped and the patient underwent a partial ovariectomy. In
the subsequent 6 months, she was treated with the gona-
dotropin-releasing hormone agonist (GnRH-a) triptoreline
at the dosage of 3.75 mg im once monthly, during which
period the patient did not present with any attack. Never-
theless, at the end of treatment at the age of 33, the MA
attacks recurred with high frequency. At that time, the
patient experienced important emotional distress due to a
severe disease suffered by her mother. At the age of 40, she
was diagnosed with a breast cancer. A radical mastectomy
was performed and pathology showed a ductal adenocar-
cinoma with metastatic invasion of the axillary
lymphonodes; estrogen and progesterone receptors were
positive. The surgery was followed by six cycles of che-
motherapy with cyclophosphamide, methotrexate and 5-
fluorouracil. During chemotherapy, the patient reported
about three crises monthly, of which one was regularly, at
the end of every cycle. After the end of chemotherapy,
tamoxifen 20 mg daily was started and the therapy lasted
for 5 years. In the 5 years of tamoxifen therapy, the patient
experienced only three attacks, but soon after the stop of
therapy MA built up again with two or three episodes a
month of severe headache preceded by visual disturbance
and paresthesia, the latter being very unusual until then. A
brain MR with gadolinium and MR-angiography were
unremarkable. Migraine prophylactic treatment was pre-
scribed with flunarizine 5 mg daily for 6 months and then
amitriptyline 50 mg at bedtime for 8 months with poor
efficacy.
Discussion
This case considers the milestones of the physiological
hormonal life of a woman and their effects on the course
of MA. Moreover, the pathologies presented by the
patient (endometriosis and breast cancer) allow to evi-
dence the importance of the treatments performed, in
particular those with influence on hormonal activity, on
MA attacks. The data, regarding the frequency of the
crises are precise because, for many years before
presenting to our Headache Centre, the patient entered in
her detailed personal diary the events of her life,
including the occurrence of the attacks and of menses.
Clearly, the trigger factors for MA are not only hormonal,
but also emotional, causes (the disease of her mother, the
neoplasia, problems in the job). However, the relation-
ships with the physiological hormonal modifications are
very evident: first of all, we notice the beginning of the
attacks a few months after menarche and the occurrence
of the attacks often in relation to menses. Then, she
developed a worsening of the attacks at the beginning of
the third month of pregnancy, an unusual but not
extraordinary circumstance in MA, that respect to
migraine without aura (MO) may show a less favourable
course or that sometimes develops during pregnancy [12].
Finally, we noted a persistence of the attacks during
puerperium and breast-feeding. Regarding pharmacologi-
cal treatments, we evidenced drugs that caused worsening
or improvement of the attacks. In the first instance, there
was a remarkable worsening of the crisis with the use of
OC, in spite of the concomitant prophylactic treatment.
Moreover, although it is difficult to establish the exact
mechanism of action by which antiblastic drugs might
provoke the attacks at the end of every treatment, a
cause–effect relationship appears clear. In the second
instance, the treatment with GnRH-a for therapy of
endometriosis and then with tamoxifen for adjuvant
treatment of the neoplasia proved to be very effective in
the prevention of the attacks, particularly tamoxifen that
was prescribed for 5 years. The patient reported not more
than three attacks during the entire period of anti-oes-
trogenic treatment. About tamoxifen, there are two studies
in the literature [13, 14]. In an open-label non-randomized
study on eight women suffering from not further specified
catamenial migraine, five patients reported marked
improvement or disappearance of headache, two mild–
moderate improvement and one was unchanged. Tamox-
ifen was given at a dosage of 10–20 mg/days for 7–
14 days before menstruation and continued at 5–10 mg
days for 3 days after the start of menstruation for four
cycles [13]. The second report was on a series of six
women with ‘‘migraine-type headaches’’ and benign
mammary dysplasia treated with tamoxifen 20 mg/day.
Improvement was seen in all patients who no longer
required migraine drug therapy, but the attacks returned a
few weeks after tamoxifen discontinuation of the drug
[14]. In contrast with these data, one case report of cat-
amenial migraine showed a worsening of the attacks with
tamoxifen [15]. We found two studies on the use of
GnRH-a with partially divergent conclusions [16, 17].
The first was a non-randomized prospective study, in
which five patients with menstrual migraine were treated
with 3.75 mg IM GnRH-a monthly for 10 months. For the
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last 6 months of treatment, patients also received trans-
dermal estrogen and medroxyprogesterone 2.5 mg. All the
patients reported a marked reduction of the attacks with
leuprolide and with leuprolide and hormonal add-back
therapy [16]. Conversely, Martin et al. [17] in a ran-
domized, placebo-controlled study on 21 patients, treated
with GnRH-a and with GnRH-a associated with estrogens,
demonstrated a modest preventive benefit only in the
group treated with GnRH-a (goserelin 3.6 mg implant)
associated with a transdermal patch containing 100 lg of
oestradiol-17b. The above reported studies, the only ones
present in literature on this topic to the best of our
knowledge, consider the use of tamoxifen and GnRHa
only in the treatment of MO. We highlight the possible
use of these treatments also in MA, but this needs further
studies. A possible caveat is that often the course of MA
is irregular with long periods of spontaneous remission
and this pattern could make testing the efficacy of a
therapy difficult. But this statement is not applicable to
our patient who presented a rather regular course of the
crisis. The uncommon behavior of MA in this patient
should be stressed. MA is commonly thought to worsen in
periods of high plasma estrogen concentration, such as the
last two trimesters of pregnancy, but not with estrogen
withdrawal. In this case, MA worsened with both low and
high estrogen levels (i.e., menstrual period, post-partum,
pregnancy). It seems that both hormonal fluctuations and
stable high estrogen levels could trigger MA attacks,
whereas stable low estrogen levels, obtained pharmaco-
logically by anti-estrogen and GnRH-a drugs, could be
beneficial. In our case, these therapies were given, inci-
dentally, to treat other diseases (endometriosis and breast
cancer) as in the Powles’ report for benign mammary
dysplasia [8]. We believe, considering these results, that
in particular and selected situations, when the crises are
particularly related to hormonal changes and difficult to
treat, or when associated with concomitant gynecologic
diseases, these drugs could be considered for use,
although not as a first-line treatment, but with caution and
in cooperation with a gynecologist.
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